Genomic medicine implementation: Learning by example

Genomic Medicine is beginning to emerge into clinical practice. The National Human Genome Research Institute's Genomic Medicine Working Group consists of organizations that have begun to implement some aspect of genomic medicine (e.g., family history, systematic implementation of Mendelian disease program, pharmacogenomics, whole exome/genome sequencing). This article concisely reviews the working group and provides a broader context for the articles in the special issue including an assessment of anticipated provider needs and ethical, legal, and social issues relevant to the implementation of genomic medicine. The challenges of implementation of innovation in clinical practice and the potential value of genomic medicine are discussed. © 2014 Wiley Periodicals, Inc.

[1]  M. Eccles,et al.  Welcome to Implementation Science , 2006, Implementation Science.

[2]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[3]  S. Shirasawa,et al.  KRAS mutation confers resistance to antibody‐dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells , 2014, International journal of cancer.

[4]  Aniwaa Owusu Obeng,et al.  Clinical pharmacogenetics implementation: Approaches, successes, and challenges , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[5]  Siobhan M. Dolan,et al.  Evaluation of a Novel Electronic Genetic Screening and Clinical Decision Support Tool in Prenatal Clinical Settings , 2014, Maternal and Child Health Journal.

[6]  Acog Practice Bulletin Clinical Management Guidelines for Obstetrician-Gynecologists Use of Psychiatric Medications During Pregnancy and Lactation , 2009 .

[7]  Soma Das,et al.  Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project” , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[8]  T. Kauf,et al.  Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV , 2012, PharmacoEconomics.

[9]  Gail P Jarvik,et al.  Return of results: Ethical and legal distinctions between research and clinical care , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[10]  Michel Wensing,et al.  What drives change? Barriers to and incentives for achieving evidence‐based practice , 2004, The Medical journal of Australia.

[11]  E. Green,et al.  Leading the way to genomic medicine , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[12]  Peter Tarczy-Hornoch,et al.  Refining the structure and content of clinical genomic reports , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[13]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy , 2011, Clinical pharmacology and therapeutics.

[14]  Ching-Hon Pui,et al.  PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[15]  Kensaku Kawamoto,et al.  Characterizing genetic variants for clinical action , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[16]  Eric D Wieben,et al.  Implementing individualized medicine into the medical practice , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[17]  Marc S. Williams,et al.  Implementation of genomic medicine in a health care delivery system: A value proposition? , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[18]  Marc S. Williams Delivery of Personalized Medicine in an Integrated Healthcare System , 2013 .

[19]  H. Faruki,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, Personalized medicine.

[20]  Carlo Gambacorti-Passerini,et al.  Part I: Milestones in personalised medicine--imatinib. , 2008, The Lancet. Oncology.